Atyr pharma inc (LIFE)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenues:
Total revenues

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

14,319

14,048

14,007

14,410

17,580

20,385

22,146

25,077

27,013

30,067

33,901

37,163

40,050

42,846

46,372

43,716

39,911

34,504

26,175

22,846

18,982

16,777

0

0

0

General and administrative

9,410

9,352

9,250

9,842

10,897

12,435

15,911

17,130

17,141

17,078

14,571

14,347

14,986

15,094

15,524

15,628

14,898

13,112

10,988

9,235

7,564

6,777

0

0

0

Total operating expenses

23,729

23,400

23,257

24,252

28,477

32,820

38,057

42,207

44,154

47,145

48,472

51,510

55,036

57,940

61,896

59,344

54,809

47,616

37,163

32,081

26,546

23,554

0

0

0

Income (loss) from operations

-15,242

-22,978

-22,979

-24,158

-28,477

-32,820

-38,057

-42,207

-44,154

-47,145

-48,472

-51,510

-55,036

-57,940

-61,896

-59,344

-54,809

-47,616

-37,163

-32,081

-26,546

-23,554

0

0

0

Other income (expense), net

-

-

-

-

-

-

-

-

-

-

-847

-438

-157

65

85

23

-209

-386

-355

-739

-782

-796

0

0

0

Total other expense, net

-632

-785

-973

-1,263

-1,508

-1,695

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Consolidated net income (loss)

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to noncontrolling interest in Pangu BioPharma Limited

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) attributable to aTyr Pharma, Inc.

-15,713

-23,603

-23,952

-25,421

-29,985

-34,515

-39,667

-43,743

-45,469

-48,207

-49,299

-51,928

-55,173

-57,855

-61,782

-59,292

-54,989

-47,973

-37,518

-32,820

-27,328

-24,350

0

0

0

Basic net income (loss) per share

0.25

-

-

-

-2.54

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used in computing basic net income (loss) per share

6,881

-

-

-

2,418

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted net income (loss) per share

0.25

-

-

-

-2.54

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used in computing diluted net income (loss) per share

6,884

-

-

-

2,418

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion to redemption value of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

416

0

0

0

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-24,766

0

0

0

Net loss per share attributable to common stockholders, basic and diluted

-

-

-1.47

-1.80

-

-7.54

-3.33

-4.88

-0.36

-24.63

-0.43

-0.51

-0.56

-0.53

-0.58

-0.65

-0.68

7.58

-0.48

-0.74

-9.39

-6.95

-8.02

-6.85

-7.87

Weighted average common stock shares outstanding, basic and diluted

-

-

3,846

3,244

-

-25,496

2,134

2,133

29,795

-65,987

25,818

23,810

23,739

23,723

23,696

23,672

23,631

23,904

23,581

14,901

966

865

843

836

791

License Revenues [Member]
Total revenues

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration Revenue [Member]
Total revenues

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-